ArticleClinical molecular pathology1995
Loss of heterozygosity in lobular carcinoma in situ of the breast.
Article in Clinical molecular pathology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 92 citations in OpenAlex.
- Lobular carcinoma in situ: diagnostic criteria and molecular correlates.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Review
- Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Lobular Carcinoma In Situ.Surgical pathology clinics · 2018Review
- Multicolor immunofluorescence reveals that p63- and/or K5-positive progenitor cells contribute to normal breast epithelium and usual ductal hyperplasia but not to low-grade intraepithelial neoplasia of the breast.Virchows Archiv : an international journal of pathology · 2017Observational
- Clonal relationships between lobular carcinoma in situ and other breast malignancies.Breast cancer research : BCR · 2016Article
- Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships.Molecular oncology · 2016Article
- Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting.Cancer medicine · 2014Article
- Lobular neoplasia: frequency and association with other breast lesions.Diagnostic pathology · 2011Article
- The molecular pathology of breast cancer progression.The Journal of pathology · 2011Review
- Preinvasive breast cancer.Annual review of pathology · 2010Review
- Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy.Annals of surgical oncology · 2008Article
- Expression of nm23 in the spectrum of pre-invasive, invasive and metastatic breast lesions.Diagnostic pathology · 2008Article
- Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers.British journal of cancer · 2006Article
- Genetic similarities and differences between lobular in situ neoplasia (LN) and invasive lobular carcinoma of the breast.Virchows Archiv : an international journal of pathology · 2006Article
- WWOX, the common chromosomal fragile site, FRA16D, cancer gene.Cytogenetic and genome research · 2003Article
- The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions.Breast cancer research : BCR · 2003Review
- E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer?Breast cancer research : BCR · 2002Review
- Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.Molecular pathology : MP · 2001Review
- Biological features of premalignant disease in the human breast.Journal of mammary gland biology and neoplasia · 2000Review
- Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene.British journal of cancer · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims-(1) To investigate whether loss of heterozygosity identified at various loci in invasive breast carcinoma or is present in lobular carcinoma in situ (LCIS). (2) To investigate whether LCIS is a monoclonal (neoplastic) or a polyclonal (hyperplastic) proliferation.Methods-Forty three cases of LCIS (30 with associated invasive carcinoma or in situ ductal carcinoma (DCIS) and 13 cases of pure LCIS) were investigated for loss of heterozygosity on chromosomes 16q, 17q, 17p, and 13q using a microdissection technique, polymorphic DNA markers, and the polymerase chain reaction (PCR).Results-Loss of heterozygosity was detected in both subgroups of LCIS at all the loci examined. There was no significant difference in the frequency of the loss between the group associated with invasive carcinoma and the pure LCIS group. The frequency of loss of heterozygosity ranged from 8% on 17p to 50% on 17q.Conclusions-Because of the nature of the technique employed, our findings show that LCIS is a monoclonal (neoplastic) proliferation rather than a hyperplastic proliferation. The incidence of loss of heterozygosity on 17p (D17S796) is lower than we have observed previously in DCIS, suggesting that LCIS and DCIS are different genetically as well as clinically and morphologically. The similar incidence of loss of heterozygosity on 16q and 17q, however, suggests that DCIS and LCIS may share a common pathway of evolution.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.